 |
|
|
|
| |
|
|
| |
|
|
| |
|
|
Mr. Woodall is the Chief Executive Officer of the Cardiovascular Research Foundation (CRF). Founded in 1991, CRF has played a key role in the development of nonsurgical and drug-based treatments of heart and vascular diseases.
During a critical era in the development of the subspecialty of interventional cardiology, from 1988 until 1996, he held the office of President of Interventional Systems Company (a division of Johnson & Johnson), leading the team responsible for developing the company's cardiovascular franchise into a $1 billion division. His tenure there included the development and launch of the PALMAZ-SCHATZ® Coronary Stent, which was designated as "the most important new medical device in the past 15 years" in a survey of medical device company CEOs in 1996. Mr. Woodall retired from Johnson & Johnson in 2001 and became the Chairman of the Board of the Lehigh Valley Hospital and Health Network, which has received multiple awards as one of the leading hospital systems in America. He has served on the Board of Directors for Doylestown Hospital. Mr. Woodall also serves on the Board of Directors of the Cardiovascular Research Foundation in New York City, the International Society of Endovascular Specialists in Phoenix, and CardioMEMs Inc., a cardiovascular device company in Atlanta.
|
|
| |
|
|
| |
|
|
|
